Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-46.05	-26.77	-62.9	-12.76	-24.52
Depreciation & Amortization	1.01	0.94	0.26	0.27	0.3
Share-Based Compensation	5.95	4.29	2.44	2.49	4.41
Other Operating Activities	5.55	2.82	16.3	8.06	-3.93
Operating Cash Flow	-33.54	-18.72	10.44	-1.94	-23.74
Capital Expenditures	-0.3	-0.09	-0.1	-0.03	-0.03
Acquisitions	-30.4	-14.09	0	0	0
Change in Investments	13.31	-22.54	-15.42	0	3.26
Investing Cash Flow	-17.39	-36.72	-15.52	-0.03	3.23
Share Issuance / Repurchase	2.88	-4.4	155.43	0	0
Debt Issued / Paid	25.59	12.75	-40.98	2.82	4.94
Other Financing Activities	-	-	-1.34	-0.08	-
Financing Cash Flow	28.46	8.35	113.11	2.74	4.94
Exchange Rate Effect	0.04	0.2	0	0	0
Net Cash Flow	-22.42	-46.88	108.02	0.77	-15.56
Free Cash Flow	-33.83	-18.81	10.34	-1.97	-23.76
Free Cash Flow Margin	-123.20%	-185.12%	36.08%	-14.84%	-185.08%
Free Cash Flow Per Share	-0.95	-0.55	0.35	-0.49	-12.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).